The primary objective of this study is to compare the effect of Amlodipine with placebo on all-cause mortality in patients with moderate to severe heart failure (NYHA III-IV) of non-ischemic etiology treated with ACE inhibitors, digoxin and diuretics. Additionally, subgroup analyses of the primary endpoint: NYHA class III vs. IV; baseline LVEF above and below the median; age; and gender will be conducted. The randomized, double-blind multicenter study will be conducted at 240 sites within the United States and Canada, with each center contributing a minimum of 8 patients for a total of approximately 1800 patients. It will consist of a screening visit, followed by a double-blind period of up to 3 years; duration to be determined by the recruitment rate, event rate and stopping rules. The study will continue until the occurrence of 264 deaths in the placebo group.
Showing the most recent 10 out of 1380 publications